PTC expects net price of $35,000 annually per patient for Emflaza
from The Wall Street Journal
PTC Therapeutics Inc. said that it would receive a net price of $35,000 annually per patient for Emflaza, the muscular dystrophy drug it acquired from Marathon Pharmaceuticals LLC last month. PTC didn’t explain how it calculated the “net price,” a term drugmakers sometimes use to describe the net revenue they receive for a drug after providing discounts, copay assistance and free medicine to patients without insurance. PTC said the $35,000 “net price” reflected how much it expected to receive from a typical pediatric patient weighing about 55 pounds.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063